Merck wins Hi-Tech case
Executive Summary
The Federal Circuit U.S. Court of Appeals on March 30 rejected Hi-Tech's novel argument that Merck's anti-glaucoma drug patent was not entitled to patent term extension because the patent had a terminal disclaimer. Such a disclaimer specifies that a drug is not "patentably distinct" from an earlier patent; Hi-Tech argued that the patent covering Trusopt (dorzolamide) and Cosopt (dorzolamide/timolol) would thus expire on the date of the previous patent (1"The Pink Sheet" Feb. 5, 2007, p. 8)...
You may also be interested in...
Patent Extension Arguments In Merck v. Hi-Tech Case Have Broad Implications
Generic manufacturer Hi-Tech Pharmacal is pursuing a unusual challenge to Merck's patent for the anti-glaucoma drug dorzolamide
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker